🇪🇺EU · EMAWithdrawn

Advasure(E2 glycoprotein of classical swine fever virus)

Marketing Authorisation Holder: Pfizer Limited

EMA Authorisation: 02/02/2001

INN: adjuvanted vaccine against classical swine fever

Indication

Active immunisation of pigs, over the age of 2 weeks, against Classical Swine Fever (CSF), to preventmortality, reduce clinical signs of the disease and the excretion of field virus.The onset of protection is 2 weeks.The duration of protection is 6 months.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Advasure — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Advasure Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.